Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516046 · ClinicalTrials.gov registry record · Phase 3
18F-AV-1451 Autopsy Study
A Phase 3 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
NCT02516046 is a Phase 3 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 156 participants.
The verdict
NCT02516046, a Phase 3 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
Study Summary
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
Interventions
- DRUG Flortaucipir F18
- PROCEDURE PET Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516046
The ClinicalTrials.gov registry entry for NCT02516046 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flortaucipir F18 is the first listed.
NCT02516046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02516046 about?
NCT02516046 is a clinical study titled "18F-AV-1451 Autopsy Study". This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
What is the current status of trial NCT02516046?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2015-09. Estimated completion is 2018-07-15.
What interventions are being tested in trial NCT02516046?
The interventions under investigation include: Flortaucipir F18 (DRUG), PET Scan (PROCEDURE).
Who is sponsoring clinical trial NCT02516046?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.